Secondary Logo

Institutional members access full text with Ovid®

Artemisinin and its derivatives

a potential treatment for leukemia

Lam, Nelson Siukeia,b,c,d,*; Long, Xinxina,b,*; Wong, Jonathan W.e,f; Griffin, Robert C.g; Doery, James C.G.c,f

doi: 10.1097/CAD.0000000000000697

Artemisinin (ART) and its derivatives are one of the most important classes of antimalarial agents, originally derived from a Chinese medicinal plant called Artemisia annua L. Beyond their outstanding antimalarial and antischistosomal activities, ART and its derivatives also possess both in-vitro and in-vivo activities against various types of cancer. Their anticancer effects range from initiation of apoptotic cell death to inhibition of cancer proliferation, metastasis and angiogenesis, and even modulation of the cell signal transduction pathway. This review provides a comprehensive update on ART and its derivatives, their mechanisms of action, and their synergistic effects with other chemicals in targeting leukemia cells. Combined with limited evidence of drug resistance and low toxicity profile, we conclude that ART and its derivatives, including dimers, trimers, and hybrids, might be a potential therapeutic alternative to current chemotherapies in combating leukemia, although more studies are necessary before they can be applied clinically.

aZhongshan School of Medicine, Sun Yat-sen University

bDepartment of Haematology, The Third Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen Institute of Hematology, Guangzhou, Guangdong, China

cDepartment of Pathology

dDepartment of Pharmacy

eDepartment of Haematology, Monash Medical Centre

fDepartment of Medicine, Monash University, Clayton, Victoria

gThe Canberra Hospital, Woden Valley, Canberra, Australia

*Nelson Siukei Lam and Xinxin Long contributed equally to the writing of this article.

Correspondence to James C.G. Doery, MD, FRCPA, Department of Pathology, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia Tel: +61 39 594 4522; fax: +61 39 594 6619; e-mail:

Received March 9, 2018

Accepted September 3, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.